secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001193125-26-206455
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotechnologies Q1 revenue $70.9M, up 35% YoY; MRD revenue up 53%; raises FY2026 MRD guidance to $260-270M
--------------------------------------------------------------------------------

- Q1 revenue $70.9M (+35% YoY); MRD revenue $67.1M (+53% YoY); clonoSEQ test volume 32,595 (+41%).
- Net loss narrowed to $20.0M from $29.8M; adj. EBITDA loss $2.5M improved from $12.7M loss.
- Raised FY2026 MRD revenue guidance to $260-270M (from $255-265M), implying 22-27% annual growth.
- Recognized $9.0M in MRD pharma regulatory milestone revenue, first U.S. primary endpoint milestone.
- Immune Medicine revenue $3.8M (-57% YoY); cash & equivalents $237.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000119312526206455/0001193125-26-206455-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000119312526206455/adpt-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-206455

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer